Tag: antidepressant side effects

The assertion that the so-called antidepressants are being over-prescribed implies that there is a correct and appropriate level of prescribing and that depression is a chronic illness (just like diabetes). It has been an integral part of psychiatry's message that although depression might have been triggered by an external event, it is essentially an illness residing within the person's neurochemistry. The issue is not whether people should or shouldn't take pills. The issue is psychiatry pushing these dangerous serotonin-disruptive chemicals on people, under the pretense that they have an illness.

Not all people who have letters after their names are actually "gods" or even people who have any special powers to know things about us more than we can learn about ourselves, about our own bodies, and our own minds. Blindly following what someone says we need to be doing for our own health (mental or physical) and well-being just because they have a white jacket on (so to speak) is usually not in our best interests.

When we set out to restore GSK’s misreported Study 329 of paroxetine for adolescent depression under the RIAT initiative, we had no idea of the magnitude of the task we were undertaking. After almost a year, we were relieved to finally complete a draft and submit it to the BMJ, who had earlier indicated an interest in publishing our restoration. But that was the beginning of another year of peer review that we believed went beyond enhancing our paper and became rather an interrogation of our honesty and integrity. Frankly, we were offended that our work was subject to such checks when papers submitted by pharmaceutical companies with fraud convictions are not.

The medication left me emotionally numb, making it impossible to connect with people or sense the aliveness of the world around me. But after two years on antidepressants, I found something that gave me jolt of feeling strong enough to wake me up for a moment. I then spent the next seven years giving myself daily doses of horror to induce an emotional reaction.

Since the 1980s, antidepressant use has risen by at least four-hundred percent and obesity rates have climbed to include thirty percent of the population....

When I was born, everyone was expecting me to have arms. The doctor's mind raced; how am I going to tell this mother and the father that their son has hands but not arms? If he's missing so much in his extremities, mustn’t he also be missing a mind? My mom looked into my eyes and knew - in a way that only mothers know - that I had a mind, and spirit.

Researchers from the State University of New York at Buffalo (UB) found that antidepressants weaken bone growth which can disrupt procedures like tooth implants....

The Scientific American reports on an in-depth reanalysis revealing widespread underreporting of negative side effects, including suicide attempts and aggressive behavior. Article →

I have a complicated response to the article Panel Calls for Depression Screenings During and After Pregnancy, by Pam Belluck, in the January 26^th New York Times, which calls for depression screening before and after pregnancy. On the face of it this sounds like a great idea - a public health measure to prevent or deal with problematic postpartum responses – baby blues, postpartum depression, postpartum psychosis.

The case of “Beth” depicts, almost innocently, the trials and tribulations of a well-adjusted, talented 15-year-old who developed depression, paranoia, panic attacks, and self-injurious and homicidal behavior, and “bipolar disorder” after being prescribed antidepressants, and then antipsychotics. After Beth decided - on her own - to discontinue psychotropic medications in favor of hormone therapy, she remained free of psychiatric symptoms.

When the idea that selective serotonin re-uptake inhibitors (SSRIs) might make people feel suicidal first started to be discussed, I admit I was sceptical. It didn’t seem to me the drugs had much effect at all, and I couldn’t understand how a chemical substance could produce a specific thought. Because these effects did not show up in randomised controlled trials, they were dismissed and few efforts were made to study them properly. Then some large meta-analyses started to find an association between the use of modern antidepressants and suicidal thoughts and actions, especially in children.

Too many people have come to view themselves as defective and powerless to change their life situations, when this may not be the case. Conversely, individual treatment with drugs or psychotherapy may cause individuals to reframe their problems in terms of neurochemistry or thinking styles – internalizing a belief that they are the problem, when their problems exist in a wider sociopolitical milieu.

What does screening mean, in the ever more prevalent field of Psychiatry? Psychiatric screening is not a biological metric that can be assumed to predict the future in a linear manner. It’s a series of subjective questions. It is, in short, a survey.

The largest-ever meta-analysis of antidepressant trials appeared yesterday in the British Medical Journal. Researchers from the Cochrane Collaboration reviewed 70 trials (involving 18,526 subjects), to find that - counter to the initially-reported findings - antidepressants doubled the risk of suicide and aggression in subjects under 18. This risk had been misrepresented in the original study reports, the authors say, and suggest that the risks to adults may be similarly under-reported.

If antidepressants are effective, and people with depression are more likely to be prescribed them, then you would expect the consequences of depression to start to lessen. One of those consequences, according to government statistics, is being out of work. But what we see is quite the opposite: Increasing use of antidepressants correlates with increased numbers of people with depression who are out of work and claiming benefits, and increasingly on a long-term basis. And this is at a time when disability due to other medical conditions has fallen.

Let us put the final nail in the coffin of the neurotransmitter myth of big Pharma and the APA. The idea that psychiatric issues come from some quantitative soup of neurotransmitters in the synapses of the brain is completely wrong. Yes there are neurotransmitters in the brain. However, serotonin does not create symptoms.

More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials.

Access to data is more important than access to information about conflicts of interest. It is only when there is access to the data that we can see if interests are conflicting and take that into account. Problems don’t get solved unless someone is motivated for some reason. We need the bias that pharmaceutical companies bring to bear in their defense of a product, along with the bias of those who might have been injured by a treatment. Both of these biases can distort the picture but it’s when people with differing points of view agree on what is right in front of their noses that we can begin to have some confidence about what we have.

One of psychiatry's most obvious vulnerabilities is the fact that various so-called antidepressant drugs induce homicidal and suicidal feelings and actions in some people, especially late adolescents and young adults. This fact is not in dispute, but psychiatry routinely downplays the risk, and insists that the benefits of these drugs outweigh any risks of actual violence that might exist.

In May 2014, the RIAT team asked GSK what the children who became suicidal in the course of Study 329 have since been told. The consent form says that anyone entering the study would be treated just the way they would be in normal clinical practice. In Study 329, the children taking imipramine were by design force titrated upwards to doses of the order of 300 mg, which is close to double the dose of imipramine given in adult trials by GSK or in normal clinical practice. In normal clinical practice it would be usual to inform somebody who had become suicidal on an SSRI that the treatment had caused their problem.

The authors of Study 329 began recruiting adolescents for a comparative study of Paxil, imipramine and placebo in 1994 and finished their investigations in 1997. They dropped a large number of their original cohort, so the randomness element in the study must be open to question. Late in 1998, SmithKline Beecham, the marketers of Paxil, acknowledged in an internal document that the study had shown that Paxil didn’t work for adolescents in terms of the two primary and six secondary outcomes they had established at the start of the study. In a nutshell, Study 329 was negative for efficacy and positive for harm, contrary to their succinct upbeat conclusion.